Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?

SIMPLE SUMMARY: Chemoimmunotherapy has been the cornerstone of the first-line treatment for chronic lymphocytic leukaemia for almost a decade: FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rixutimab) regimens for fit patients and G-CLB (obinutuzumab, chlorambucil) being the mos...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolej, Lukáš, Vodárek, Pavel, Écsiová, Dominika, Šimkovič, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267736/
https://www.ncbi.nlm.nih.gov/pubmed/34201565
http://dx.doi.org/10.3390/cancers13133134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267736/
https://www.ncbi.nlm.nih.gov/pubmed/34201565
http://dx.doi.org/10.3390/cancers13133134

Ejemplares similares